Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q14142
UPID:
TRI14_HUMAN
Alternative names:
-
Alternative UPACC:
Q14142; A8K9W0; E7EQC4; F8W956; Q548W9; Q5TBQ8; Q6ZWL7; Q9BRD8; Q9C020
Background:
Tripartite motif-containing protein 14 (TRIM14) is pivotal in the innate immune defense against viruses and bacteria. It enhances the type I interferon (IFN) response by facilitating the interaction between MAVS and IKBKG/NEMO at the mitochondria, leading to activation of IRF3 and NF-kappa-B pathways. TRIM14 also stabilizes CGAS, preventing its degradation, and acts as a scaffold for TBK1 and STAT3, promoting STAT3 phosphorylation to resolve interferon-stimulated gene expression. Additionally, it modulates SPI1 transcriptional activity.
Therapeutic significance:
Understanding the role of Tripartite motif-containing protein 14 could open doors to potential therapeutic strategies.